* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
A mixture of <strong>[53967-21-8]6-(bromomethyl)quinoxaline</strong> (900 mg, 4.0 mmol), 6-methyl-2- sulfanylpyrimidin-4-ol (440 mg, 3.1 mmol), and triethylamine (1.1 mL, 7.8 mmol) in absolute ethanol (20 mL) was stirred at room temperature overnight. The reaction mixture was evaporated and then co-evaporated with EtOAc. The solid residue was treated with water (100 mL). The solid product was recovered by filtration, washed with water (2 x 20 mL), diethyl ether (3 x 20 mL), and hexanes (3 x 20 mL), and then dried in vacuo, affording 6-methyl-2-[(quinoxalin-6-ylmethyl)sulfanyl]pyrimidin-4-ol (658 mg, 75% yield). The product was used without further purification.
6-methyl-2-(2-morpholino-2-oxoethylthio)pyrimidin-4(3H)-one[ No CAS ]
Yield
Reaction Conditions
Operation in experiment
54%
With potassium carbonate; In N,N-dimethyl-formamide;
General procedure: A mixture of compound 14 (300 mg, 2,1 mmol), 2-bromo-1-(4-methoxyphenyl)ethanone (483 mg, 2.1 mmol) and potassiumcarbonate (291 mg, 2.1 mmol) was stirred in anhydrous N,Ndimethylformamide(3 mL) at room temperature for 12 h. Completionof the reaction was monitored by TLC. The reaction contentwas poured on cold water (5 mL) and extracted with ethyl acetate(3 10 mL). The organic layers were combined together, washedwith brine (1 10 mL), dried over anhydrous sodium sulfate andthe solvent was evaporated to dryness. The crude mixture waspurified by column chromatography (hexanes:ethyl acetate gradient)to obtain pure compound 15A as a pale yellow (306 mg, 50%).
Chemistry
Pharmaceutical Intermediates
Inhibitors/Agonists
Material Science
For Research Only
120K+ Compounds
Competitive Price
1-2 Day Shipping
